New drug combo aims to control Hard-to-Treat blood cancer

NCT ID NCT07032714

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Apr 14, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This early-stage study tests two drugs, mezigdomide and talquetamab, in people with multiple myeloma that has come back or not responded to treatment. The goal is to find the safest dose and see how well the combination controls the cancer. About 25 adults will take part, receiving the drugs in a specific order to manage side effects and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)